NYSEAMERICAN:ATNM - Actinium Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.38 +0.01 (+2.70 %)
(As of 05/23/2018 02:44 PM ET)
Previous Close$0.38
Today's Range$0.37 - $0.38
52-Week Range$0.33 - $1.50
Volume4,100 shs
Average Volume839,597 shs
Market Capitalization$32.44 million
P/E RatioN/A
Dividend YieldN/A
Beta40.64

About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals logoActinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Receive ATNM News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:ATNM
CUSIPN/A
Phone+1-646-6773875

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-187.42%
Return on Assets-146.18%

Miscellaneous

EmployeesN/A
Outstanding Shares110,200,000

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) announced its quarterly earnings results on Monday, March, 16th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. View Actinium Pharmaceuticals' Earnings History.

What price target have analysts set for ATNM?

4 brokerages have issued 12-month target prices for Actinium Pharmaceuticals' shares. Their predictions range from $3.00 to $6.00. On average, they expect Actinium Pharmaceuticals' stock price to reach $4.50 in the next twelve months. View Analyst Ratings for Actinium Pharmaceuticals.

What are Wall Street analysts saying about Actinium Pharmaceuticals stock?

Here are some recent quotes from research analysts about Actinium Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company's principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. " (5/22/2018)
  • 2. Maxim Group analysts commented, "Actinium presented a poster: A Phase 2 Study of Actinium-225 (225Ac)- Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy"." (12/6/2017)

Are investors shorting Actinium Pharmaceuticals?

Actinium Pharmaceuticals saw a decrease in short interest during the month of April. As of April 30th, there was short interest totalling 803,996 shares, a decrease of 33.3% from the April 13th total of 1,205,816 shares. Based on an average daily trading volume, of 802,307 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.7% of the company's stock are short sold.

Who are some of Actinium Pharmaceuticals' key competitors?

Who are Actinium Pharmaceuticals' key executives?

Actinium Pharmaceuticals' management team includes the folowing people:
  • Mr. Sandesh C. Seth, Exec. Chairman and Chief Exec. Officer (Age 54)
  • Mr. Steven O'Loughlin BS, Principal Financial & Accounting Officer and VP of Fin. & Corp. Devel. (Age 32)
  • Dr. Mark S. Berger M.D., Chief Medical Officer (Age 63)
  • Dr. Nitya G. Ray Ph.D., Exec. VP and Head of Product Devel., Manufacturing & Supply Chain (Age 65)
  • Dr. Dale L. Ludwig, Chief Scientific Officer

Has Actinium Pharmaceuticals been receiving favorable news coverage?

Media stories about ATNM stock have trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Actinium Pharmaceuticals earned a media sentiment score of 0.06 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.30 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Actinium Pharmaceuticals' major shareholders?

Actinium Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Anson Funds Management LP (3.73%), Sabby Management LLC (1.81%), Sio Capital Management LLC (0.98%) and Worth Venture Partners LLC (0.35%). Company insiders that own Actinium Pharmaceuticals stock include Ajit Shetty, Nitya G Ray, Sandesh Seth, Sloan-Kettering Cance Memorial and Steve O'loughlin. View Institutional Ownership Trends for Actinium Pharmaceuticals.

Which institutional investors are buying Actinium Pharmaceuticals stock?

ATNM stock was purchased by a variety of institutional investors in the last quarter, including Anson Funds Management LP, Sabby Management LLC, Sio Capital Management LLC and Worth Venture Partners LLC. Company insiders that have bought Actinium Pharmaceuticals stock in the last two years include Ajit Shetty, Nitya G Ray, Sandesh Seth and Steve O'loughlin. View Insider Buying and Selling for Actinium Pharmaceuticals.

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Actinium Pharmaceuticals' stock price today?

One share of ATNM stock can currently be purchased for approximately $0.38.

How big of a company is Actinium Pharmaceuticals?

Actinium Pharmaceuticals has a market capitalization of $32.44 million.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875.


MarketBeat Community Rating for Actinium Pharmaceuticals (ATNM)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  213
MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe ATNM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Actinium Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.50, suggesting that the stock has a possible upside of 1,084.21%. The high price target for ATNM is $6.00 and the low price target for ATNM is $3.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.50$4.50$4.50$5.00
Price Target Upside: 1,084.21% upside1,116.22% upside662.71% upside719.67% upside

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Consensus Price Target History

Price Target History for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
3/28/2018Maxim GroupSet Price TargetBuy$3.00View Rating Details
3/14/2018B. RileySet Price TargetBuy$3.00View Rating Details
10/23/2017HC WainwrightReiterated RatingBuy$6.00View Rating Details
10/23/2017Roth CapitalReiterated RatingBuy$6.00View Rating Details
11/2/2016FBR & CoReiterated RatingBuy$9.00View Rating Details
(Data available from 5/23/2016 forward)

Earnings

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Earnings History and Estimates Chart

Earnings by Quarter for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Earnings Estimates

2018 EPS Consensus Estimate: ($0.38)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.09)($0.09)($0.09)
Q2 20181($0.09)($0.09)($0.09)
Q3 20181($0.10)($0.10)($0.10)
Q4 20181($0.10)($0.10)($0.10)

Actinium Pharmaceuticals (NYSEAMERICAN ATNM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2017Q2 2017($0.14)($0.12)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.13)($0.14)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.12)ViewN/AView Earnings Details
10/28/2016Q3 2016($0.15)ViewN/AView Earnings Details
7/29/2016Q2 2016($0.15)($0.15)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.15)($0.14)ViewN/AView Earnings Details
3/11/2016Q4 2015($0.16)ViewN/AView Earnings Details
10/30/2015Q3 2015($0.16)($0.10)ViewN/AView Earnings Details
8/7/2015Q2 2015($0.20)ViewN/AView Earnings Details
5/8/2015Q1 2015($0.09)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.19)($0.17)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Actinium Pharmaceuticals (NYSEAMERICAN ATNM) Insider Trading and Institutional Ownership History

Insider Trading History for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)
Institutional Ownership by Quarter for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals (NYSEAMERICAN ATNM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/19/2018Sandesh SethCEOBuy5,000$0.38$1,900.00View SEC Filing  
2/28/2018Ajit ShettyDirectorBuy22,730$0.43$9,773.90View SEC Filing  
8/2/2017Nitya G RayInsiderBuy10,000$0.75$7,500.0010,000View SEC Filing  
8/2/2017Sandesh SethCEOBuy33,333$0.75$24,999.7575,833View SEC Filing  
6/15/2017Sandesh SethChairmanBuy7,500$1.16$8,700.0037,500View SEC Filing  
6/15/2017Steve O'loughlinInsiderBuy3,500$1.17$4,095.003,500View SEC Filing  
12/30/2016Sandesh SethInsiderBuy5,000$0.88$4,400.0035,000View SEC Filing  
12/12/2016Sandesh SethInsiderBuy5,000$0.98$4,900.0030,000View SEC Filing  
8/31/2016Sloan-Kettering Cance MemorialMajor ShareholderSell192,927$1.83$353,056.414,878,988View SEC Filing  
8/29/2016Sloan-Kettering Cance MemorialMajor ShareholderSell50,000$1.71$85,500.004,939,490View SEC Filing  
8/16/2016Sloan-Kettering Cance MemorialMajor ShareholderSell9,468$1.72$16,284.964,957,517View SEC Filing  
7/12/2016Sloan-Kettering Cance MemorialMajor ShareholderSell3,100$1.80$5,580.004,962,056View SEC Filing  
7/11/2016Sloan-Kettering Cance MemorialMajor ShareholderSell21,990$1.80$39,582.004,965,856View SEC Filing  
7/6/2016Sloan-Kettering Cance MemorialMajor ShareholderSell20,840$1.81$37,720.405,001,886View SEC Filing  
7/1/2016Sloan-Kettering Cance MemorialMajor ShareholderSell148,100$1.81$268,061.005,140,786View SEC Filing  
6/15/2016Sloan-Kettering Cance MemorialMajor ShareholderSell33,619$1.90$63,876.105,155,986View SEC Filing  
6/2/2016Sloan-Kettering Cance MemorialMajor ShareholderSell17,790$2.01$35,757.905,196,395View SEC Filing  
6/1/2016Sloan-Kettering Cance MemorialMajor ShareholderSell169,450$1.97$333,816.505,358,735View SEC Filing  
5/26/2016Sloan-Kettering Cance MemorialMajor ShareholderSell40,068$1.92$76,930.565,389,745View SEC Filing  
5/25/2016Sloan-Kettering Cance MemorialMajor ShareholderSell36,400$1.90$69,160.005,427,313View SEC Filing  
4/26/2016Sloan-Kettering Cance MemorialMajor ShareholderSell52,577$2.04$107,257.085,502,849View SEC Filing  
4/21/2016Sloan-Kettering Cance MemorialMajor ShareholderSell196,497$2.03$398,888.915,652,878View SEC Filing  
4/18/2016Sandesh SethChairmanBuy15,000$1.99$29,850.0015,000View SEC Filing  
4/15/2016Sergio TraversaDirectorBuy3,000$2.02$6,060.002,000View SEC Filing  
4/14/2016Kaushik J DaveCEOBuy10,000$2.02$20,200.0086,500View SEC Filing  
4/14/2016Richard I SteinhartDirectorBuy2,500$2.01$5,025.002,500View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Actinium Pharmaceuticals (NYSEAMERICAN ATNM) News Headlines

Source:
DateHeadline
Actinium Pharmaceuticals (ATNM) Sees Significant Decline in Short InterestActinium Pharmaceuticals (ATNM) Sees Significant Decline in Short Interest
www.americanbankingnews.com - May 10 at 1:39 AM
Actinium Pharmaceuticals to Present at 19th Annual Bio€quity Europe Conference in Ghent, BelgiumActinium Pharmaceuticals to Present at 19th Annual Bio€quity Europe Conference in Ghent, Belgium
finance.yahoo.com - May 8 at 10:11 AM
Actinium Pharmaceuticals: Neglected Assets In Niche OncologyActinium Pharmaceuticals: Neglected Assets In Niche Oncology
seekingalpha.com - May 4 at 3:51 PM
Actinium Pharmaceuticals Appoints Dr. Jeffrey Chell, Bone Marrow Transplant Visionary and Chief Executive Officer Emeritus of Be The Match and National Marrow Donor Program, to its Board of DirectorsActinium Pharmaceuticals Appoints Dr. Jeffrey Chell, Bone Marrow Transplant Visionary and Chief Executive Officer Emeritus of Be The Match and National Marrow Donor Program, to its Board of Directors
finance.yahoo.com - May 1 at 10:17 AM
Actinium Pharmaceuticals (ATNM) Sees Large Increase in Short InterestActinium Pharmaceuticals (ATNM) Sees Large Increase in Short Interest
www.americanbankingnews.com - April 24 at 6:38 PM
Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team withActinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with
www.nasdaq.com - April 18 at 10:27 AM
Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical DevelopmentActinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical Development
finance.yahoo.com - April 18 at 10:27 AM
Actinium Pharmaceuticals to Showcase Capabilities of its AWE Technology Platform in Developing Biobetters at Upcoming AACR Annual MeetingActinium Pharmaceuticals to Showcase Capabilities of its AWE Technology Platform in Developing Biobetters at Upcoming AACR Annual Meeting
finance.yahoo.com - April 11 at 11:02 AM
Actinium Pharmaceuticals (ATNM) Short Interest UpdateActinium Pharmaceuticals (ATNM) Short Interest Update
www.americanbankingnews.com - April 11 at 2:04 AM
Actinium Pharmaceuticals (ATNM) Upgraded by Zacks Investment Research to BuyActinium Pharmaceuticals (ATNM) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - April 5 at 5:46 PM
Maxim Group Reaffirms Buy Rating for Actinium Pharmaceuticals (ATNM)Maxim Group Reaffirms Buy Rating for Actinium Pharmaceuticals (ATNM)
www.americanbankingnews.com - April 5 at 2:40 PM
Actinium Pharmaceuticals (ATNM) Given a $3.00 Price Target by Maxim Group AnalystsActinium Pharmaceuticals (ATNM) Given a $3.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - March 28 at 11:27 AM
Actinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform TechnologyActinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform Technology
finance.yahoo.com - March 28 at 10:25 AM
Short Interest in Actinium Pharmaceuticals Inc (ATNM) Declines By 44.2%Short Interest in Actinium Pharmaceuticals Inc (ATNM) Declines By 44.2%
www.americanbankingnews.com - March 27 at 1:02 AM
Maxim Group Analysts Give Actinium Pharmaceuticals (ATNM) a $3.00 Price TargetMaxim Group Analysts Give Actinium Pharmaceuticals (ATNM) a $3.00 Price Target
www.americanbankingnews.com - March 20 at 10:41 AM
Actinium Pharmaceuticals (ATNM) Given a $3.00 Price Target at B. RileyActinium Pharmaceuticals (ATNM) Given a $3.00 Price Target at B. Riley
www.americanbankingnews.com - March 17 at 9:58 PM
Actinium Pharmaceuticals to Present at 28th Annual Oppenheimer Healthcare ConferenceActinium Pharmaceuticals to Present at 28th Annual Oppenheimer Healthcare Conference
finance.yahoo.com - March 15 at 11:09 AM
Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of ... - GlobeNewswire (press release)Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of ... - GlobeNewswire (press release)
globenewswire.com - March 14 at 3:47 PM
Actinium Pharma (ATNM) Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with R/R AMLActinium Pharma (ATNM) Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with R/R AML
www.streetinsider.com - March 14 at 11:28 AM
Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients ... - NasdaqActinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients ... - Nasdaq
www.nasdaq.com - March 13 at 3:53 PM
Actinium Pharma (ATNM) Announces FDA Clearance of IND For ... - StreetInsider.comActinium Pharma (ATNM) Announces FDA Clearance of IND For ... - StreetInsider.com
www.streetinsider.com - March 13 at 3:53 PM
Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AMLActinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
finance.yahoo.com - March 13 at 11:23 AM
Short Interest in Actinium Pharmaceuticals Inc (ATNM) Expands By 91.3%Short Interest in Actinium Pharmaceuticals Inc (ATNM) Expands By 91.3%
www.americanbankingnews.com - March 9 at 6:24 PM
Actinium Pharmaceuticals to Present at 30th Annual ROTH Conference - GlobeNewswire (press release)Actinium Pharmaceuticals to Present at 30th Annual ROTH Conference - GlobeNewswire (press release)
globenewswire.com - March 7 at 3:45 PM
Actinium Announces $15.4 Million in Expected Gross Proceeds from ... - GlobeNewswire (press release)Actinium Announces $15.4 Million in Expected Gross Proceeds from ... - GlobeNewswire (press release)
globenewswire.com - March 5 at 3:54 PM
Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual ... - GlobeNewswire (press release)Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual ... - GlobeNewswire (press release)
globenewswire.com - March 1 at 3:45 PM
Active-Investors: Wired News - Actinium Pharma Announced Activation of Sixteen Clinical Trial Sites in Phase-3 SIERRA Trial for Iomab-BActive-Investors: Wired News - Actinium Pharma Announced Activation of Sixteen Clinical Trial Sites in Phase-3 SIERRA Trial for Iomab-B
www.finanznachrichten.de - March 1 at 10:26 AM
Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant OrganizationsActinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations
finance.yahoo.com - February 28 at 10:46 AM
Actinium Pharmaceuticals Inc (ATNM) Short Interest UpdateActinium Pharmaceuticals Inc (ATNM) Short Interest Update
www.americanbankingnews.com - February 28 at 1:08 AM
Actinium Pharma (ATNM) Announces Activation of Sixteenth Clinical ... - StreetInsider.comActinium Pharma (ATNM) Announces Activation of Sixteenth Clinical ... - StreetInsider.com
www.streetinsider.com - February 27 at 3:47 PM
Actinium Pharmaceuticals Announces Activation of Sixteenth Clinical Trial Site in the Pivotal Phase 3 SIERRA Trial for Iomab-BActinium Pharmaceuticals Announces Activation of Sixteenth Clinical Trial Site in the Pivotal Phase 3 SIERRA Trial for Iomab-B
finance.yahoo.com - February 27 at 10:58 AM
Actinium Pharmaceuticals Reiterates Previously Announced Expiration Date of March 2, 2018 at 5:00 PM ET and ... - GlobeNewswire (press release)Actinium Pharmaceuticals Reiterates Previously Announced Expiration Date of March 2, 2018 at 5:00 PM ET and ... - GlobeNewswire (press release)
globenewswire.com - February 26 at 3:41 PM
Mid-Afternoon Market Update: Telaria Falls Following Q4 Results; Achillion Pharmaceuticals Shares Surge - BenzingaMid-Afternoon Market Update: Telaria Falls Following Q4 Results; Achillion Pharmaceuticals Shares Surge - Benzinga
www.benzinga.com - February 26 at 3:41 PM
Actinium Pharmaceuticals Announces Commencement of Rights Offering Subscription Period - GlobeNewswire (press release)Actinium Pharmaceuticals Announces Commencement of Rights Offering Subscription Period - GlobeNewswire (press release)
globenewswire.com - February 22 at 3:46 PM
Actinium Pharmaceuticals Announces Commencement of Rights Offering Subscription PeriodActinium Pharmaceuticals Announces Commencement of Rights Offering Subscription Period
finance.yahoo.com - February 22 at 10:24 AM
Actinium Pharmaceuticals Announces Product Showcase and Other ... - GlobeNewswire (press release)Actinium Pharmaceuticals Announces Product Showcase and Other ... - GlobeNewswire (press release)
globenewswire.com - February 20 at 3:42 PM
Actinium Pharmaceuticals (ATNM) Given a $3.00 Price Target by B. Riley AnalystsActinium Pharmaceuticals (ATNM) Given a $3.00 Price Target by B. Riley Analysts
www.americanbankingnews.com - February 16 at 8:46 PM
Actinium Pharma (ATNM) Reports Submission of IND For Actimab-A in Combination with CLAG-M for Patients with R/R ... - StreetInsider.comActinium Pharma (ATNM) Reports Submission of IND For Actimab-A in Combination with CLAG-M for Patients with R/R ... - StreetInsider.com
www.streetinsider.com - February 13 at 5:51 AM
Actinium Announces Submission of IND For Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AMLActinium Announces Submission of IND For Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
finance.yahoo.com - February 13 at 5:51 AM
Actinium Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of RecordActinium Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record
finance.yahoo.com - February 12 at 3:19 PM
Short Interest in Actinium Pharmaceuticals Inc (ATNM) Expands By 8.0%Short Interest in Actinium Pharmaceuticals Inc (ATNM) Expands By 8.0%
www.americanbankingnews.com - February 9 at 8:06 PM
Actinium Appoints Anil Kapur as Chief Commercial Officer to Build ... - GlobeNewswire (press release)Actinium Appoints Anil Kapur as Chief Commercial Officer to Build ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 3:18 PM
Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on MyeloablationActinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation
finance.yahoo.com - February 8 at 3:18 PM
Actinium Pharmaceuticals Reminds Investors of Record Date for ... - GlobeNewswire (press release)Actinium Pharmaceuticals Reminds Investors of Record Date for ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 5:28 AM
Actinium Pharmaceuticals Reminds Investors of Record Date for Rights OfferingActinium Pharmaceuticals Reminds Investors of Record Date for Rights Offering
finance.yahoo.com - February 8 at 5:28 AM
Actinium Pharma (ATNM) Reports Trial to Study Actimab-A in ... - StreetInsider.comActinium Pharma (ATNM) Reports Trial to Study Actimab-A in ... - StreetInsider.com
www.streetinsider.com - February 6 at 3:19 PM
Actinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML PatientsActinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients
finance.yahoo.com - February 6 at 3:19 PM
Actinium Pharmaceuticals to Present at the BIO CEO & Investor ConferenceActinium Pharmaceuticals to Present at the BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 5:36 AM
Actinium Pharma (ATNM) Announces Rights Offering - StreetInsider.comActinium Pharma (ATNM) Announces Rights Offering - StreetInsider.com
www.streetinsider.com - February 2 at 3:19 PM
Actinium Pharma (ATNM) Announces Rights OfferingActinium Pharma (ATNM) Announces Rights Offering
www.streetinsider.com - February 2 at 5:42 AM

SEC Filings

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Actinium Pharmaceuticals (NYSEAMERICAN ATNM) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.